Cannabinoid Biosciences, Inc. (“CBDZ”) is a biopharmaceutical company, which intends to engage in the discovery, development and commercialization of cures and novel therapeutics from proprietary cannabinoid, cannabidiol, endocannabinoids, phytocannabinoids, and synthetic cannabinoids product platform suitable for specific treatments in a broad range of disease areas. The Company intends to operate through Research and Development, and Pipeline Acquisition. The Company intends to commercialize its products through collaborations with pharmaceutical companies for the specific treatments of diseases and medical conditions.
CBDZ's mission is to revolutionize and standardize the pharmaceuticals and non-pharmaceutical CBD products formulation across the CBD market in the United States of America and to some extent, globally. CBDZ seeks to control the production and distribution of verities of consumer cannabidiol (CBD) formulation under private brands in the United States. CBDZ’s goal is to bring standardization to the CBD industry, the same way that John D Rockefeller’s Standard Oil brought standardization to crude refining in the United States in the nineteenth century. CBDZ’s product lineup include tinctures, capsules, gummies, bath bombs, vape oils, topical creams, and animal treats and oils. The company will sell its products directly to consumers through the company Website, as well as non-affiliated stores in about 40 states. The company was founded in 2014 and is based in Los Angeles, California. https://cbdxfund.com/invest/
The company is also engaged in the following areas of the legal cannabis business: (1) Ownership interest in certain dispensaries and cultivation facilities; (2) financial products in form of asset-backed loans, business property mortgages and other financial products to qualified individuals/businesses in the legal-cannabis businesses; and (3) professional services including top-level financial reporting, Accounting, CSE Reporting, Business Valuation, Mergers & Acquisitions, GAAP/ IFRS Conversion, Pre IPO/RTO Prep, Section 280E Tax, and Biological Assets Valuation to cannabis businesses and investors in California at first, then to those within the other states that has legalized cannabis.
Cannabinoid Biosciences (CBDZ) is not a public company quoted on any of the know exchanges. CBDZ is currently working with several owners of dispensaries and cultivation facilities to rollup ten of these dispensary and IPO it on the nasdaq or New York stock exchange.
Our experienced management team has a combined sixteen years of successful experience in the legal cannabis industry in California. Cannabinoid Biosciences is launching throughout California and bringing its array of investments and services to each new state that legalizes the use of cannabis.
CBDZ wants to facilitate, invest-in, and support development and commercialization of cures and novel therapeutics from proprietary cannabinoid. This mission also entails providing financing and turnkey support services to the legal cannabis industry in the U.S. Our goal is to invest in, and lend to legal Cannabis businesses as well as build an array of turnkey solutions to open model dispensaries, production facilities, and product companies operating as community stewards for good business practice.
Two of our business units are in flux and have investment opportunities that we want to capitalize upon immediately:
Opportunities for Rollup and Consolidation
CBDZ (WWW.CBDXFUND.COM) has agreed to rollup 10 dispensaries with $54 million in annual revenue. These rollup will IPO on the NASDAQ or NYSE and Canadian Securities Exchange (CSE) via Reg. A+, which is already filed with the SEC. Our Reg A+ was qualified by te SEC on April 16, 2019. We therefore intend to raise the $50 million, purchase the 10 targets, and get listed on the NASDAQ or NYSE. A $1,000 invested at this ground floor could fetch a lot more post-IPO because NASDAQ and NYSE market-participants pay between $131-$215 price to sale multiples for rollup/consolidated Cannabis businesses.
We need to raise $50 million to acquire ≥10 dispensaries which we’ll rollup into our holding company and IPO on the NASDAQ or New York Stock Exchange.All our targeted acquisitions are profitable operations.We plan to keep 50% of the profits for future growth, and pay 50% back to our investors as dividends.
Our proforma financial projection showed that this rollup could be worth $4.6 billion on the stock exchange once CBDZ have finished rollup and consolidation of all the 10 dispensaries and cultivation facilities.This valuation is based on the weighted average multiple of X-sales and X-net profit of cannabis businesses currently trading on the exchanges.
We are currently reviewing transfer agents to see who is most likely to help our objectives of becoming Nasdaq-listed within 12-36 months.May, 2019
Good news. Our Reg A+ Tier 2 Offering Circular has been qualified by the US Securities and Exchange Commission (SEC) on April 16, 2019.April, 2019
CBDZ is negotiating with the largest Indian reservation in Portland, Oregon to secure a large land to grow cannabis and to open a dispensaryDecember, 2018
As part of this agreement, CBDZ would acquire all prior invention of the scientist including all cannabis/hemp based formulations.December, 2018
CBDZ is in the middle of negotiating employment agreement with certain CBD/THC scientist as a Chief Scientific Officer, to join our team.December, 2018
Finalized Regulation D 506(c) offering for its Secured Convertible Note paying 8% annual interest. A $1,000 Note is convertible into 80December, 2018
Filed Regulation A+ with the U.S. Securities and Exchange Commission (SEC).December, 2018
Company was formedMay, 2014